| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275) (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Noga EJ, Udomkusonsri P: Fluorescein: a rapid, sensitive, nonlethal method for detecting skin ulceration in fish. Vet Pathol. 2002 Nov;39(6):726-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12450204 (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...ugbank/indication
| - For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Fluorescein sodium is used extensively as a diagnostic tool in the field of ophthalmology. Fluorescein is a fluorescent compound or fluorophore having a maximum absorbance of 494 m and an emission maximum of 521 nm. The yellowish-green fluorescence of the compound can be used to demarcate the vascular area under observation, distinguishing it from adjacent areas. It is applied topically in the form of a drop or it can be injected intravenously to produce a fluorescein angiogram. Topical fluorescein is a useful tool in the diagnosis of corneal abrasions, corneal ulcers, herpetic corneal infections, and dry eye. Fluorescein angiography is used to diagnose and categorize macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...outeOfElimination
| - Fluorescein and its metabolites are mainly eliminated via renal excretion. (en)
|
| http://linked.open.../drugbank/synonym
| - 3',6'-dihydroxyfluoran (en)
- 3,6-fluorandiol (en)
- 9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone (en)
- 9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one (en)
- C.I. Solvent Yellow 94 (en)
- D and C Yellow No. 7 (en)
- D&C Yellow No. 7 (en)
- Fluoresceine (en)
- Fluoreszein (en)
- Japan Yellow 201 (en)
- Resorcinolphthalein (en)
- Solvent Yellow 94 (en)
- Yellow fluorescein (en)
|
| http://linked.open...umeOfDistribution
| |
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open.../drugbank/mixture
| |
| http://linked.open...nk/proteinBinding
| |
| http://linked.open...ogy/drugbank/salt
| |
| http://linked.open...ynthesisReference
| - Richard T. Dean, Conrad P. Dorn, Jr., Tsung-Ying Shen, "Fluorescein esters and ethers and the preparation thereof." U.S. Patent US4304720, issued January, 1972. (en)
|
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...ogy/drugbank/logS
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...nd-Acceptor-Count
| |
| http://linked.open...-Bond-Donor-Count
| |
| http://linked.open...drugbank/InChIKey
| |
| http://linked.open...urface-Area--PSA-
| |
| http://linked.open...nk/Polarizability
| |
| http://linked.open...bank/Refractivity
| |
| http://linked.open...atable-Bond-Count
| |
| http://linked.open...ugbank/absorption
| |
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...rugbank/clearance
| - * renal cl=1.75 mL/min/kg [After IV administration] * hepatic cl=1.50 mL/min/kg [After IV administration] (en)
|
| http://linked.open...gbank/containedIn
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)